Clinical Trials

    Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers

    Investigator: Jun Zhang

    Study Coordinator: Gabrielle Hayes

    Status: Open Not Enrolling

    ClinicalTrials.gov Number: NCT02595944

    Phone: 734.415.918

    Protocol Number: Pro00016419

    Description


    This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in different ways and kill tumor cells remaining after surgery and standard of care chemotherapy.